Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - Seite 2

Oral and Paper Presentations: TearCare System

• Tear Break-up, Meibomian Gland, and Dry Eye Symptom Improvement for Cyclosporine-Treated Patients after Localized Heat Therapy Treatment (SAHARA Cross-Over/phase 2) – oral presentation on Sunday, April 7 at 3:30 PM ET at the BCEC Meeting level 2, room 259B. Lead author: Brandon Ayres, MD
• Rapid Improvement in the Signs and Symptoms of Dry Eye Disease with Localized Heat Therapy (LHT) or Cyclosporine Ophthalmic Emulsion (CsA) (SAHARA subanalysis) – poster presentation. Lead author: Julio Echegoyen, MD, PhD
• Localized Heat Therapy (LHT) Compared to Cyclosporine Ophthalmic Emulsion (CsA): A Subanalysis on Age, Gender, and Disease Burden (SAHARA subanalysis) – poster presentation. Lead author: Jennifer Loh, MD
  

“These data once again support the conclusion that TearCare should be a preferred treatment for DED associated with meibomian gland dysfunction,” says Brandon Ayres, MD, of Wills Eye Hospital, Philadelphia, PA. “In phase 1 of the SAHARA trial, we found the interventional TearCare procedure provided statistically superior and sustained improvement in tear break-up time and multiple measures of meibomian gland secretion when compared to treatment with Restasis.³ In phase 2 (cross-over) of the study, we found that a single TearCare procedure improved signs and symptoms for patients beyond what was achieved with six months of Restasis.”

Red Carpet Event
Additionally, at ASCRS, Sight Sciences will be hosting a red carpet event at its booth (#545), where the company will celebrate its shared commitment to elevating eyecare for the benefit of patients. The event will be on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM ET. Learn more about this and other Sight Sciences activities at ASCRS at www.sightsciences.com/ascrs

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world’s leading cause of irreversible blindness. The SION Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company’s TearCare System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. Visit sightsciences.com for more information.